A staging system has been developed to revise the 1994 ARCO classification for ONFH. The final consensus resulted in the following 4-staged system: stage I—X-ray is normal, but either magnetic resonance imaging or bone scan is positive; stage II—X-ray is abnormal (subtle signs of osteosclerosis, focal osteoporosis, or cystic change in the femoral head) but without any evidence of subchondral fracture, fracture in the necrotic portion, or flattening of the femoral head; stage III—fracture in the subchondral or necrotic zone as seen on X-ray or computed tomography scans. This stage is further divided into stage IIIA (early, femoral head depression ≤2 mm) and stage IIIB (late, femoral head depression >2 mm); and stage IV—X-ray evidence of osteoarthritis with accompanying joint space narrowing, acetabular changes, and/or joint destruction. Radiographs, magnetic resonance imaging (MRI), and computed tomography (CT) scans may all be involved in diagnosing ONFH; however, the optimal diagnostic modality remains unclear. The purpose of this study was to identify: 1) how ONFH is diagnosed at a single academic medical center, and 2) if CT is a necessary modality for diagnosing/staging OFNH. The EMR was queried for the diagnosis of ONFH between 1/1/2008–12/31/2018 at a single academic medical center. CT and MRI scans were reviewed by the senior author and other contributors. The timing and staging quality of the diagnosis of ONFH were compared between MRI and CT to determine if CT was a necessary component of the ONFH work-up.Introduction
Methods
Patients who have multiple sclerosis (MS) may be at increased risk of developing complications after total hip arthroplasty (THA). The purpose of this study was to compare: 1) implant survivorship; 2) functional outcomes; 3) complication rates; and 4) radiographic findings after THA between MS patients and a matched cohort. A single institutional database was reviewed for patients who had a diagnosis of MS and underwent a THA. Thirty-four patients (41 hips) were matched to a 2:1 cohort who did not have MS using based on age, sex, body mass index (BMI), and Charlson/Deyo scores. This resulted in a matching cohort of 80 patients (82 hips). The available medical records were reviewed. Functional outcomes and complications were assessed. Postoperative radiographs were evaluated. The matching cohort had higher all-cause survivorship at 4-years postoperatively (99 vs. 93%). There were 3 revisions in the MS cohort and 0 revisions in the matching cohort. The MS cohort had lower mHHS scores (66 vs.74 points, p<0.001), lower HOOS JR scores (79 vs. 88 points, p<0.01), required more physical therapy (5 vs. 3 weeks, p<0.01), and took longer to return to their baseline functional level (7 vs. 5 weeks, p<0.05). MS patients had higher rate of complications (6 vs. 1, p<0.05). Excluding revision cases, there was no additional radiographic evidence of progressive radiolucency, loosening, or subsidence. We found that MS patients had lower implant survivorship, lower functional outcome scores, and increased complication rates. These findings may help orthopaedists to have a better knowledge of how MS patients do after THA.
